The company's ability to hold off generic competitors long enough to develop a pair of replacement drugs for Humira that are ...

Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.

A blockbuster drug is a best-selling medication earning over $1 billion annually. Learn about them and how they revolutionize ...

To combat rising costs, BCBSM installed a multi-year cost-cutting initiative to slice $600 million off its total spend, which has resulted in hundreds of job losses at the insurer. A total of 1,300 ...

The report reviews the challenge of ASP erosion in Medicare Part B and policy solutions that could ensure patients have access to biosimilars.

A new report paints a stark picture of how a subset of large healthcare providers are drawing the lion’s share of 340B savings within a single state.  | A Minnesota analysis of providers' reported ...

Well, good morning, everybody, and thank you once again for joining us for the 46th Annual TD Cowen Healthcare Conference. I'm Yaron Werber from the biotech team, and it's a great pleasure to moderate ...

The insurer said it reduced administrative costs, adjusted prices and benefited from investment gains. But payouts for member care and benefits rose.

After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its up-and-coming immunology powerhouse. | Two years and five indications later ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsRoopal Thakkar - Executive VP of Research ...

By no means is this the first large-scale attempt to address the drug pricing problem in America. TrumpRx joins a long list of programs that aim to make drugs more affordable without actually making ...

AbbVie (ABBV) has drawn fresh investor attention after reporting positive Phase 3 AFFIRM trial results for risankizumab in ...